INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.

Our primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin and programmable combination drug delivery devices.

The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level.